Low efficacy of nevirapine (HIVNET012) in preventing perinatal HIV-1 transmission in a real-life situation.
Since 2001, the unrestricted use of HIVNET012 has been recommended for the prevention of mother-to-child transmission in low-resource settings, despite the lack of validated efficacy data outside research settings. We implemented the nevirapine regimen in a real-life situation in Kenya. The perinatal HIV-1 transmission rate at 14 weeks was 18.1%, similar to the 21.7% before the intervention. These data call for further evaluation of the simple nevirapine regimen in field conditions, and underline the need for alter-native strategies.
International Centre for Reproductive Health, Ghent University, Ghent, Belgium.
Ann
A
Quaghebeur
Lillian
L
Mutunga
Fabian
F
Mwanyumba
Kishor
K
Mandaliya
Chris
C
Verhofstede
Marleen
M
Temmerman
D019380:Anti-HIV Agents / Q000627:therapeutic use*; D005260:Female; D015658:HIV Infections / Q000517:prevention & control*; D015497:HIV-1; D006801:Humans; D019829:Nevirapine / Q000627:therapeutic use*; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000517:prevention & control*
D019380:Anti-HIV Agents; D019829:Nevirapine